Movement Alert｜Moderna, Inc. Falls 3.25% in Pre-Market Trading, Convertible Note Hedging Pressure Persists Amid Biotech Sector Weakness

Market Focus09-02 20:27

On September 2, Moderna, Inc. fell 3.25% in pre-market trading, trading at $149.62/share, with turnover of $18.18 million.

The decline reflects lingering selling pressure from the company's recently priced $2.6 billion zero-coupon convertible senior notes due 2032, upsized from an initially planned $2 billion offering. Arbitrage hedging activity associated with the convertible issuance continues to weigh on the stock. Meanwhile, peer BioNTech's announcement terminating its colorectal cancer vaccine Phase 2 clinical trial has dampened broader biotech sector sentiment, creating a drag on related names including Moderna, Inc..

Despite at least five institutions — including Argus Research (target $180), Barclays (target raised to $125 from $48), and JPMorgan (target raised to $77 from $40) — upgrading or raising price targets following the successful Phase 3 readout of its personalized mRNA melanoma cancer vaccine co-developed with Merck, the Wall Street consensus rating remains at hold with a mean target of $96.47. The market has yet to reach a unified view on cancer vaccine commercialization prospects, leaving the stock in a volatile price re-rating phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177363181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177363181","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Moderna, Inc. Falls 3.25% in Pre-Market Trading, Convertible Note Hedging Pressure Persists Amid Biotech Sector Weakness","media":"Market Focus","content":"<p><p>On September 2, Moderna, Inc. fell 3.25% in pre-market trading, trading at $149.62/share, with turnover of $18.18 million.</p><p>The decline reflects lingering selling pressure from the company's recently priced $2.6 billion zero-coupon convertible senior notes due 2032, upsized from an initially planned $2 billion offering. Arbitrage hedging activity associated with the convertible issuance continues to weigh on the stock. Meanwhile, peer BioNTech's announcement terminating its colorectal cancer vaccine Phase 2 clinical trial has dampened broader biotech sector sentiment, creating a drag on related names including Moderna, Inc..</p><p>Despite at least five institutions — including Argus Research (target $180), Barclays (target raised to $125 from $48), and JPMorgan (target raised to $77 from $40) — upgrading or raising price targets following the successful Phase 3 readout of its personalized mRNA melanoma cancer vaccine co-developed with Merck, the Wall Street consensus rating remains at hold with a mean target of $96.47. The market has yet to reach a unified view on cancer vaccine commercialization prospects, leaving the stock in a volatile price re-rating phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Falls 3.25% in Pre-Market Trading, Convertible Note Hedging Pressure Persists Amid Biotech Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Falls 3.25% in Pre-Market Trading, Convertible Note Hedging Pressure Persists Amid Biotech Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-02 20:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 2, Moderna, Inc. fell 3.25% in pre-market trading, trading at $149.62/share, with turnover of $18.18 million.</p><p>The decline reflects lingering selling pressure from the company's recently priced $2.6 billion zero-coupon convertible senior notes due 2032, upsized from an initially planned $2 billion offering. Arbitrage hedging activity associated with the convertible issuance continues to weigh on the stock. Meanwhile, peer BioNTech's announcement terminating its colorectal cancer vaccine Phase 2 clinical trial has dampened broader biotech sector sentiment, creating a drag on related names including Moderna, Inc..</p><p>Despite at least five institutions — including Argus Research (target $180), Barclays (target raised to $125 from $48), and JPMorgan (target raised to $77 from $40) — upgrading or raising price targets following the successful Phase 3 readout of its personalized mRNA melanoma cancer vaccine co-developed with Merck, the Wall Street consensus rating remains at hold with a mean target of $96.47. The market has yet to reach a unified view on cancer vaccine commercialization prospects, leaving the stock in a volatile price re-rating phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1177363181","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177363181","pubTimestamp":1788352058,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 2, Moderna, Inc. fell 3.25% in pre-market trading, trading at $149.62/share, with turnover of $18.18 million.The decline reflects lingering selling pressure from the company's recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"走势警报|Moderna, Inc. 盘前交易下跌 3.25%，生物技术板块疲软，可转换票据对冲压力持续","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/03829074bec3c8961562350ec9d11b05","symbols_score_info":{"MRNA":1},"content_text":"On September 2, Moderna, Inc. fell 3.25% in pre-market trading, trading at $149.62/share, with turnover of $18.18 million.The decline reflects lingering selling pressure from the company's recently priced $2.6 billion zero-coupon convertible senior notes due 2032, upsized from an initially planned $2 billion offering. Arbitrage hedging activity associated with the convertible issuance continues to weigh on the stock. Meanwhile, peer BioNTech's announcement terminating its colorectal cancer vaccine Phase 2 clinical trial has dampened broader biotech sector sentiment, creating a drag on related names including Moderna, Inc..Despite at least five institutions — including Argus Research (target $180), Barclays (target raised to $125 from $48), and JPMorgan (target raised to $77 from $40) — upgrading or raising price targets following the successful Phase 3 readout of its personalized mRNA melanoma cancer vaccine co-developed with Merck, the Wall Street consensus rating remains at hold with a mean target of $96.47. The market has yet to reach a unified view on cancer vaccine commercialization prospects, leaving the stock in a volatile price re-rating phase.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177363181","isCrawlerRequest":true}